Cardiovascular disease

Baptiste, P. J., Wong, A. Y. S., Schultze, A., Clase, C. M., Leyrat, C., Williamson, E., et al. (2024). Cardiorenal effects of Angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers in people underrepresented in trials: analysis of routinely collected data with emulation of a reference trial (ONTARGET). Am J Epidemiol. http://doi.org/10.1093/aje/kwae137
View
Graul, E. L., Nordon, C., Rhodes, K., Menon, S., Ammouri, A., Kallis, C., et al. (2024). Factors associated with non-fatal heart failure and atrial fibrillation or flutter within the first 30 days post COPD exacerbation: a nested case-control study. Bmc Pulm Med, 24, 221. http://doi.org/10.1186/s12890-024-03035-4
View
Graul, E. L., Nordon, C., Rhodes, K., Marshall, J., Menon, S., Kallis, C., et al. (2023). Temporal Risk of Non-Fatal Cardiovascular Events Post COPD Exacerbation: A Population-based Study. Am J Respir Crit Care Med. http://doi.org/10.1164/rccm.202307-1122OC
View
Akyea, R. K., Ntaios, G., & Doehner, W. (2023). Obesity, metabolic health and clinical outcomes after incident cardiovascular disease: A nationwide population-based cohort study. J Cachexia Sarcopenia Muscle. http://doi.org/10.1002/jcsm.13340
View
Abrahami, D., D'Andrea, E., Yin, H., Kim, S. C., Paik, J. M., Wexler, D., et al. (2023). Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom. Diabetes Obes Metab. http://doi.org/10.1111/dom.15196
View
Chudasama, Y. V., Khunti, K., Coles, B., Gillies, C. L., Islam, N., Rowlands, A. V., et al. (2023). Life expectancy following a cardiovascular event in individuals with and without type 2 diabetes: A UK multi-ethnic population-based observational study. Nutr Metab Cardiovasc Dis. http://doi.org/10.1016/j.numecd.2023.04.003
View
Jordan, K. P., Rathod-Mistry, T., van der Windt, D. A., Bailey, J., Chen, Y., Clarson, L., et al. (2023). Determining cardiovascular risk in patients with unattributed chest pain in UK primary care: an electronic health record study. Eur J Prev Cardiol. http://doi.org/10.1093/eurjpc/zwad055
View
Wambua, S., Crowe, F., Thangaratinam, S., O'Reilly, D., McCowan, C., Brophy, S., et al. (2022). Protocol for development and validation of postpartum cardiovascular disease (CVD) risk prediction model incorporating reproductive and pregnancy-related candidate predictors. Diagn Progn Res, 6, 23. http://doi.org/10.1186/s41512-022-00137-7
View
group, D. I. A. L. 2 working. (2022). Estimating individual lifetime risk of incident cardiovascular events in adults with type 2 diabetes: an update and geographical calibration of the DIAbetes Lifetime perspective model (DIAL2). Eur J Prev Cardiol. http://doi.org/10.1093/eurjpc/zwac232
View
Idris, I., Zhang, R., Mamza, J. B., Ford, M., Morris, T., Banerjee, A., & Khunti, K. (2021). Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease. Diabetes Obes Metab, 23, 2207-2214. http://doi.org/10.1111/dom.14437
View